Evidence-based treatments for irritable bowel syndrome with constipation

Journal of Family Practice

Volumn 58, Issue 5 SUPPL., 2009, Pages

  Heitkemper, Margaret M ^a,b,c  

^a Elizabeth Sterling Soule

^b West Indies

^c Center for Women's   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ISPAGULA; LACTULOSE; LAXATIVE; LUBIPROSTONE; MACROGOL; PLACEBO; POLYCARBOPHIL; PROBIOTIC AGENT; PRUCALOPRIDE; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; BEHAVIOR THERAPY; BIFIDOBACTERIUM; BLOATING; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONSTIPATION; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; EVIDENCE BASED PRACTICE; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HIGH FIBER DIET; HUMAN; HYPNOSIS; IRRITABLE COLON; LACTOBACILLUS; NAUSEA; PERCEPTION; QUALITY OF LIFE; RELAXATION TRAINING; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 66949165878     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. American College of Gastroenterology Task Force on IBS. An evidence-based systematic review on the management of irritable bowel syndrome. Am I Gastroenterol. 2009;104 (suppl 1):S1-S35.
2. Hungin AP, Chang L, Locke GR, Dennis EH, Barg-hout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21:1365-1375.
3. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part 2: Lower gastrointestinal diseases. Gastroenterology. 2009;136:1134-1144.
4. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syn-drome. Gastroenterology. 2002;123:2108-2131.
5. Zaman A. Irritable bowel syndrome. Clin Corner-stone. 2002;4:22-33.
6. Lacy BE, Rosemore J, Robertson D, et al. Physi-cians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand I Gastroenterol. 2006;41:892-902.
7. Verne GN. The public awareness of the preva-lence and impact of irritable bowel syndrome in the United States: perception versus reality. J Clin Gastroenterol. 2004;38:419-424.
8. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40, 000 sub-jects. Aliment Pharmacol Ther. 2003; 17:643-650.
9. Saito YA, Locke GR, Talley NJ, et al. A compari-son of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol. 2000;95:2816-2824.
10. Saito YA, Schoenfeld P, Locke GR III. The epide-miology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910-1915.
11. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ III. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101:927-934.
12. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMI. 1992;304:87-90.
13. Tillisch K, Labus JS, Naliboff BD, et al. Character-ization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gas-troenterol. 2005;100:896-904.
14. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
15. Mearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroen-terol Hepatol. 2003;15:165-172.
16. El Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 2003;3 (suppl 2):S3-S11.
17. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syn-drome on health-related quality of life. Gastroen-terology. 2000;119:654-660.
18. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastro-enterol. 2001;96:3122-3129.
19. Levy RL, Whitehead WE, Von Korff MR, et al. Inter-generational transmission of gastrointestinal illness behavior. Am J Gastroenterol. 2000;95:451-456.
20. Drossman DA, Li Z, Andruzzi E, et al. US house-holder survey of functional gastrointestinal disor-ders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569-1580.
21. Dean BB, Aguilar D, Barghout V et al. Impairment in work productivity and health-related qual-ity of life in patients with IBS. Am J Manag Care. 2005; 11 (suppl 1):S17-S26.
22. Moynihan NT, Callahan MJ, Kalsmith B, Moses PL. How do you spell relief for irritable bowel syn-drome? J Fam Pract. 2008;57:100-108.
23. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional ab-dominal pain. Gut. 1999;45 (suppl 2):II43-II47.
24. International Foundation for Functional Gastro-intestinal Disorders. IBS in the real world survey. AboutlBSorg. 2002. http://www.aboutibs.org/pdfs/ IBSRealWorld.pdf. Accessed April 9, 2009.
25. Dancey CP, Backhouse S. Towards a better un-derstanding of patients with irritable bowel syn-drome. J Adv Nurs. 1993;18:1443-1450.
26. Kennedy A, Robinson A, Rogers A. Incorporating patients' views and experiences of life with IBS in the development of an evidence based self-help guidebook. Patient Educ Couns. 2003;50:303-310.
27. Meadows LM, Lackner S, Belic M. Irritable bowel syndrome. An exploration of the patient perspec-tive. Clin Nurs Res. 1997;6:156-170.
28. Lacy BE, Weiser K, Noddin L, et al. Irritable bowel syndrome: patients' attitudes, concerns and level of knowledge. Aliment Pharmacol Ther. 2007;25:1329-1341.
29. Halpert AD, Thomas AC, Hu Y, et al. A survey on patient educational needs in irritable bowel syn-drome and attitudes toward participation in clini-cal research. I Clin Gastroenterol. 2006;40:37-43. 30. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and prac-tical management. Gut. 2007;56:1770-1798.
30. Pleis JR, et al. Summary health statistics for US adults: National Health Interview Survey, 2007 (provisional report). Vital Health Stat 10. 2008;240:1-88.
31. Whitehead WE, Palsson O, Jones KR. System-atic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002; 122:1140-1156.
32. Whitehead WE, Palsson OS, Levy RR, et al. Co-morbidity in irritable bowel syndrome. Am J Gas-troenterol. 2007;102:2767-2776.
33. Sperber AD, Carmel S, Atzmon Y, et al. Use of the Functional Bowel Disorder Severity Index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Am I Gastro-enterol. 2000;95:995-998.
34. Nojkov B, Rubenstein JH, Adlis SA, et al. The in-fluence of co-morbid IBS and psychological dis-tress on outcomes and quality of life following PPI therapy inpatients withgastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27:473-482.
35. Dickman R, Feroze H, Fass R. Gastroesophageal reflux disease and irritable bowel syndrome: a common overlap syndrome. Curr Gastroenterol Rep. 2006;8:261-265.
36. Jung HK, Haider S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther. 2007;26:453-461.
37. Nastaskin I, Mehdikhani E, Conklin J, Park S, Pi-mentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci. 2006;51:2113-2120.
38. Rey E, Garcia-Alonso M, Moreno-Ortega M, et al. Influence of psychological distress on character-istics of symptoms in patients with GERD: The role of IBS comorbidity. Dig Dis Sci. 2008;54:321-327.
39. Ruigomez A, Wallander MA, Johansson S, et al. Irritable bowel syndrome and gastroesophageal reflux disease in primary care: Is there a link? Dig Dis Sci. 2008;54:1079-1086.
40. Cain KC, Jarrett ME, Burr RL, et al. Gender dif-ferences in gastrointestinal, psychological, and somatic symptoms in irritable bowel syndrome. Dig Dis Sci. 2008 Nov. 1 [Epub ahead of print].
41. Nicholl BI, Haider SL, Macfarlane GJ, et al. Psy-chosocial risk markers for new onset irritable bowel syndrome-results of a large prospective population-based study. Pain. 2008;137:147-155.
42. Riedl A, Schmidtmann M, Stengel A, et al. Somatic comorbidities of irritable bowel syndrome: a sys-tematic analysis. J Psychosom Res. 2008;64:573-582.
43. Spiegel BM, Kanwal F, Naliboff B, Mayer E. The impact of somatization on the use of gastroin-testinal health-care resources in patients with irritable bowel syndrome. Am I Gastroenterol. 2005;100:2262-2273.
44. Vandvik PO, Wilhelmsen I, Ihlebaek C, Farup PG. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther. 2004;20:1195-1203.
45. Longsrreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroen-terology. 2004;126:1665-1673.
46. Longsrreth GF. Avoiding unnecessary surgery in irritable bowel syndrome. Gut. 2007;56:608-610.
47. Spiegel BM. Do physicians follow evidence-based guidelines in the diagnostic work-up of IBS? Nat Clin Pract Gastroenterol Hepatol. 2007;4:296-297.
48. Bertram S, Kurland M, Lydick E, Locke GR, III, Yawn BP. The patient's perspective of irritable bowel syndrome. J Fam Pract. 2001;50:521-525.
49. Dancey CP, Fox R, Devins GM. The measurement of irritable bowel syndrome (IBS)-related mis-conceptions in people with IBS. J Psychosom Res. 1999;47:269-276.
50. Halpert A, Dalton CB, Palsson O, et al. What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educa-tional Needs Questionnaire (PEQ). Am J Gastro-enterol. 2007;102:1972-1982.
51. O'Sullivan MA, Mahmud N, Kelleher DP, Lovett E, O'Morain CA. Patient knowledge and educa-tional needs in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2000;12:39-43.
52. Kettell J, Jones R, Lydeard S. Reasons for con-sultation in irritable bowel syndrome: symp-toms and patient characteristics. Br J Gen Pract. 1992;42:459-461.
53. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroen-terol. 1997;32:920-924.
54. Cash BD, Chang L, Sabesin SM, Vitat P. Update on the management of adults with chronic idio-pathic constipation. J Fam Pract. 2007;56 (suppl 6 update):S13-S19.
55. Halpert A, Dalton CB, Palsson O, et al. Patient educational media preferences for information about irritable bowel syndrome (IBS). Dig Dis Sci. 2008;53:3184-3190.
56. Morisky DE, DeMuth NM, Field-Fass M, Green LW, Levine DM. Evaluation of family health education to build social support for long-term control of high blood pressure. Health Educ Q. 1985;12:35-50.
57. Vinicor F, Cohen SJ, Mazzuca SA, et al. DIABEDS: a randomized trial of the effects of physician and/or patient education on diabetes patient out-comes. I Chronic Dis. 1987;40:345-356.
58. Liu C, Feekery C. Can asthma education im-prove clinical outcomes? An evaluation of a pediatric asthma education program. J Asthma. 2001;38:269-278.
59. Lein C, Wills CE. Using patient-centered inter-viewing skills to manage complex patient en-counters in primary care. J Am Acad Nurse Pract. 2007;19:215-220.
60. Dontje K, Corser W, Kreulen G, Teitelman A. A unique set of interactions: the MSU sustained partnership model of nurse practitioner primary care. J Am Acad Nurse Pract. 2004;16:63-69.
61. Drossman DA, Li Z, Leserman J, Toomey TC, Hu YJ. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology. 1996, 110:999-1007.
62. Stewart M, Brown JB, Donner A, et al. The im-pact of patient-centered care on outcomes. J Fam Pract. 2000;49:796-804.
63. Kruis W, Thieme C, Weinzierl M, et al. A diag-nostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastro-enterology. 1984;87:1-7.
64. Manning AP, Thompson WG, Heaton KW, Mor-ris AF. Towards positive diagnosis of the irritable bowel. Br Med J.1978;2:653-654.
65. Heaton KW, O'Donnell LI, Braddon FE, et al. Symptoms of irritable bowel syndrome in a Brit-ish urban community: consulters and noncon-sulters. Gastroenterology. 1992;102:1962-1967.
66. Drossman DA, Whitehead WE, Camilleri M. Ir-ritable bowel syndrome: a technical review for practice guideline development. Gastroenterol-ogy. 1997;112:2120-2137.
67. Talley NJ. Differentiating functional constipation from constipation-predominant irritable bowel syndrome: management implications. Rev Gas-troenterol Disord. 2005;5:1-9.
68. Drossman DA, Morris CB, Hu Y, et al. A prospec-tive assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gas-troenterology. 2005;128:580-589.
69. Ersryd A, Posserud I, Abrahamsson H, Simren M. Subtyping the irritable bowel syndrome by pre-dominant bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther. 2007;26:953-961.
70. Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am I Gastroenterol. 1999;94:2929-2935.
71. Talley NJ, Dennis EH, Schettler-Duncan VA, et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenter-ol. 2003;98:2454-2459.
72. Rangnekar AS, Morgan D, Knechtges P, et al. Com-plaints suggestive of irritable bowel syndrome are common in patients with puborectalis dyssyn-ergia: an under-recognized overlap syndrome. Gastroenterology. 2008;134:A423.
73. Frank L, Kleinman L, Rentz A, et al. Health-re-lated quality of life associated with irritable bowel syndrome: comparison with other chronic dis-eases. Clin Ther. 2002;24:675-689.
74. Rubenstein JH, Nojkov B, Korsnes S, et al. Oe-sophageal hypersensitivity is associated with features of psychiatric disorders and the irri-table bowel syndrome. Aliment Pharmacol Ther. 2007;26:443-452.
75. Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Mo-til. 2008;20 (suppl 1):121-129.
76. Chey WD, Cash BD. Irritable bowel syndrome: update on colonic neuromuscular dysfunction and treatment. Curr Gastroenterol Rep. 2006;8:273-281.
77. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological mark-er of patients with irritable bowel syndrome. Gas-troenterology. 1995;109:40-52.
78. Di Stefano M, Miceli E, Mazzocchi S, et al. Visceral hypersensitivity and intolerance symptoms in lactose malabsorption. Neurogastroenterol Moti. 2007;19:887-895.
79. Silverman DH, Munakata JA, Ennes H, et al. Re-gional cerebral activity in normal and pathologi-cal perception of visceral pain. Gastroenterology. 1997;112:64-72.
80. Mertz H, Morgan V, Tanner G, et al. Regional ce-rebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology. 2000;118:842-848.
81. Whitehead WE, Palsson OS, Feld AD, et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther. 2006;24:137-146.
82. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome pa-tients: a systematic review. Am J Gastroenterol. 2002;97:2812-2819.
83. Majewski M, McCallum RW. Results of small in-testinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and ef-fects of antibiotic trial. Adv Med Sci. 2007;52:139-142.
84. Lupascu A, Gabrielli M, Lauritano EC, et al. Hy-drogen glucose breath test to detect small intesti-nal bacterial overgrowth: a prevalence case-con-trol study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157-1160.
85. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a dou-ble-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-419.
86. Posserud I, Stotzer PO, Bjornsson ES, Abrahams-son H, Simren M. Small intestinal bacterial over-growth in patients with irritable bowel syndrome. Gut. 2007;56:802-808.
87. Saad RJ, Chey WD. Breath tests for gastrointesti-nal disease: the real deal or just a lot of hot air? Gastroenterology. 2007;133:1763-1766.
88. Francis CY, Duffy JN, Whorwell PJ, Martin DF. Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome? Am J Gastroenterol. 1996;91:1348-1350.
89. Saito YA, Talley NJ. Genetics of irritable bowel syn-drome. Am J Gastroenterol. 2008;103:2100-2104.
90. Saito YA, Strege PR, Tester DJ, et al. Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol. 2009;296:G211-G218.
91. Cash BD, Chey WD. Diagnosis of irritable bow-el syndrome. Gastroenterol Clin North Am. 2005;34:205-20, vi.
92. Harris LR, Roberts L. Treatments for irritable bowel syndrome: patients' attitudes and accept-ability. BMC Complement Altern Med. 2008;8:65.
93. Jain N, Astin JA. Barriers to acceptance: an ex-ploratory study of complementary/alternative medicine disuse. J Altern Complement Med. 2001;7:689-696.
94. Monsbakken KW, Vandvik PO, Farup PG. Per-ceived food intolerance in subjects with irritable bowel syndrome-etiology, prevalence and con-sequences. Eur J Clin Nutr. 2006;60:667-672.
95. Simren M, Mansson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion. 2001;63:108-115.
96. Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dys-pepsia? A systematic review. Neurogastroenterol Motil. 2006;18:595-607.
97. Jones VA, McLaughlan P, Shorthouse M, Work-man E, Hunter JO. Food intolerance: a major factor in the pathogenesis of irritable bowel syn-drome. Lancet. 1982;2:1115-1117.
98. McKee AM, Prior A, Whorwell PJ. Exclusion diets in irritable bowel syndrome: are they worthwhile? J Clin Gastroenterol. 1987;9:526-528.
99. Muller-Lissner SA, Kaatz V, Brandt W, Keller J, Layer P. The perceived effect of various foods and beverages on stool consistency. Eur J Gastroen-terol Hepatol. 2005;17:109-112.
100. Sen S, Dear KL, King TS, Elia M, Hunter JO. Evalu-ation of hydrogen excretion after lactulose admin-istration as a screening test for causes of irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14:753-756.
101. Goldstein R, Braverman D, Stankiewicz H. Carbo-hydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syn-drome and functional bowel complaints. Isr Med Assoc J. 2000;2:583-587.
102. Rumessen JJ, Gudmand-Hoyer E. Functional bowel disease: malabsorption and abdominal distress after ingestion of fructose, sorbitol, and fructose-sorbitol mixtures. Gastroenterology. 1988;95:694-700.
103. Macfarlane GT, Cummings JH. Probiotics and prebiotics: can regulating the activities of intes-tinal bacteria benefit health? BMJ. 1999;318:999-1003.
104. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut. 2008 Dec. 17 [Epub ahead of print].
105. O'Mahony L, McCarthy J, Kelly P, et al. Lactoba-cillus and bifidobacterium in irritable bowel syn-drome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-551.
106. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syn-drome. Am J Gastroenterol. 2006;101:1581-1590.
107. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treat-ment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr. 2005;24:925-931.
108. Simren M, Syrous A, Lindh A, Abrahamsson H. Effects of Lactobacillus Plantarum 299V on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS)-a randomized double blind controlled trial. Gastroenterology. 2006;130 (suppl 2):A600.
109. Nobaek S, Johansson ML, Molin G, Ahme S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloat-ing and pain in patients with irritable bowel syn-drome. Am J Gastroenterol. 2000;95:1231-1238.
110. Hoveyda N, Heneghan C, Mahtani KR, et al. A sys-tematic review and meta-analysis: Probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009;9:15.
111. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fi-bre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313.
112. Cook IJ, Irvine EJ, Campbell D, et al. Effect of di-etary fiber on symptoms and rectosigmoid mo-tility in patients with irritable bowel syndrome. A controlled, crossover study. Gastroenterology. 1990;98:66-72.
113. Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irri-table bowel syndrome. Aliment Pharmacol Ther. 1993;7:87-92.
114. Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Ali-ment Pharmacol Ther. 1994;8:511-514.
115. Arffmann S, Andersen JR, Hegnhoj J, et al. The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study. Scand J Gastroenterol. 1985;20:295-298.
116. Khoshoo V Armstead C, Landry L. Effect of a laxa-tive with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23: 191-196.
117. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syn-drome: systematic review and meta-analysis. Gut. 2009;58:367-378.
118. Jarrett M, Heitkemper M, Czyzewski DI, Shulman R. Recurrent abdominal pain in children: fore-runner to adult irritable bowel syndrome? J Spec Pediatr Nurs. 2003;8:81-89.
119. Hertig VL, Cain KC, Jarrett ME, Burr RL, Heitkem-per MM. Daily stress and gastrointestinal symp-toms in women with irritable bowel syndrome. Nurs Res. 2007;56:399-406.
120. Park HJ, Jarrett M, Cain K, Heitkemper M. Psy-chological distress and GI symptoms are related to severity of bloating in women with irritable bowel syndrome. Res Nurs Health. 2008;31:98-107.
121. Heitkemper MM, Cain KC, Jarrett ME, et al. Re-lationship of bloating to other GI and menstrual symptoms in women with irritable bowel syn-drome. Dig Dis Sci. 2004;49:88-95.
122. Zijdenbos IL, de Wit NJ, van der Heijden GJ, Ru-bin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev. 2009;CD006442.
123. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. Pain affect encoded in human an-terior cingulate but not somatosensory cortex. Science. 1997;277:968-971.
124. Simren M. Hypnosis for irritable bowel syndrome: the quest for the mechanism of action. Int J Clin Exp Hypn. 2006;54:65-84.
125. Galovski TE, Blanchard EB. The treatment of ir-ritable bowel syndrome with hypnotherapy. Appl Psychophysiol Biofeedback. 1998;23:219-232.
126. Simren M, Ringstrom G, Bjomsson ES, Abraha-msson H. Treatment with hypnotherapy reduces the sensory and motor component of the gastro-colonic response in irritable bowel syndrome. Psychosom Med. 2004;66:233-238.
127. Shaw G, Srivastava ED, Sadlier M, et al. Stress management for irritable bowel syndrome: a con-trolled trial. Digestion. 1991;50:36-42.
128. Sanders KA, Blanchard EB, Sykes MA. Prelimi-nary study of a self-administered treatment for ir-ritable bowel syndrome: comparison to a wait list control group. Appl Psychophysiol Biofeedback. 2007;32:111-119.
129. Heitkemper MM, Jarrett ME, Levy RL, et al. Self-management for women with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2:585-596.
130. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neu-rogastroenterol Motil. 2008;20:99-112.
131. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in pa-tients dissatisfied with laxatives. Gut. 2009;58:357-365.
132. Lubiprostone: RU 0211, SPI 0211. Drugs R D. 2005;6:245-248.
133. Rivkin A, Chagan L. Lubiprostone: chloride chan-nel activator for chronic constipation. Clin Ther. 2006;28:2008-2021.
134. Amitiza (lubiprostone) capsules [product infor-mation]. Bethesda, MD: Sucampo Pharmaceuti-cals, Inc., and Deerfield, IL: Takeda Pharmaceu-ticals America, Inc.; 2008.
135. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubipros-tone for irritable bowel syndrome with constipa-tion. Aliment Pharmacol Ther. 2008;27:685-696.
136. Lubiprostone capsules [product information] Bethesda, MD: Sucampo Pharmaceuticals, Inc., and Deerfield, IL: Takeda Pharmaceuticals Amer-ica, Inc.; 2008.
137. Drossman DA, Chey WD, Johanson JF, et al. Clini-cal trial: lubiprostone in patients with constipa-tion-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29:329-341.
138. Clouse RE. Antidepressants for irritable bowel syndrome. Gut. 2003;52:598-599.
139. Clouse RE. Managing functional bowel disorders from the top down: lessons from a well-designed treatment trial. Gastroenterology. 2003;125:249-253.
140. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet. 2002;360:555-564.
141. Masand PS, Gupta S, Schwartz TL, et al. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin Psychiatry. 2005;7:162-166.
142. Masand PS, Gupta S, Schwartz TL, et al. Parox-etine in patients with irritable bowel syndrome: A pilot open-label study. Prim Care Companion J Clin Psychiatry. 2002;4:12-16.
143. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irri-table bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther. 2005;22:381-385.
144. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal tran-sit times in health and irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:159-166.
145. National Collaborating Centre for Nursing and Supportive Care. Clinical practice guideline: Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care. National Institute for Health and Clinical Excellence, United Kingdom. Feb. 1, 2008:1-554. http://www.nice.org.uk/ niceme-dia/pdf/IBSFullGuideline.pdf. Accessed April 9, 2009.
146. Webb AN, Kukuruzovic RH, Catto-Smith AG, Saw-yer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2007;CD005110.